ReviewArchives of disease in childhood2014
Management of Kawasaki disease.
Review in Archives of disease in childhood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.
- Association of ITPKC gene polymorphisms rs28493229 and rs2290692 in North Indian children with Kawasaki disease.Pediatric research · 2022Pooled it
- Corticosteroids for the treatment of Kawasaki disease in children.The Cochrane database of systematic reviews · 2022Pooled it
- Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease.Italian journal of pediatrics · 2021Guideline
- Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children.Frontiers in immunology · 2021Pooled it
- Risk Factors of Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease: A Meta-Analysis of Case-Control Studies.Frontiers in pediatrics · 2020Pooled it
- Effect of Early Intravenous Immunoglobulin Therapy in Kawasaki Disease: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2020Pooled it
- Corticosteroids for the treatment of Kawasaki disease in children.The Cochrane database of systematic reviews · 2017Pooled it
- Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Infantile Kawasaki Disease Mimicking Polyarteritis Nodosa With Severe Ischemic Complications: A Case Report.Cureus · 2026Article
- Kawasaki disease in Latvia 2012-2019: epidemiology and rate of resistance to initial treatment.Archives of medical science : AMS · 2026Article
- How Children with Kawasaki Disease Take Acetylsalicylic Acid Mini-Tablets at Home for the Prescribed Period.Journal of clinical medicine · 2025Article
- Fatal late cardiovascular sequelae of previously unrecognized Kawasaki disease in 12-year-old child.International journal of emergency medicine · 2025Article
- Review
- Linking Kawasaki Disease to Mental Health: A Nationwide Study on Long-Term Neurological Risks.Medicina (Kaunas, Lithuania) · 2025Article
- MFG-E8 in Kawasaki Disease: Role in Endothelial Injury and Diagnostic Potential.Journal of inflammation research · 2025Article
- Polymorphism-driven immune disruptions in Kawasaki disease across populations: decoding the role of T and B-cells.Frontiers in immunology · 2025Review
- The protective role of steroids on coronary arteries in the acute phase of Kawasaki disease for high risk patients: a retrospective study.Frontiers in pediatrics · 2025Article
- Age-Specific Cardiovascular and Platelet Dynamics in Kawasaki Disease.International journal of general medicine · 2025Article
- Atypical Kawasaki disease with giant coronary artery aneurysms in a 2-month-old boy: a case report.Journal of medical case reports · 2024Article
- Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. In developed countries KD is the commonest cause of acquired heart disease in childhood. The aetiology of KD remains unknown, and it is currently believed that one or more as yet unidentified infectious agents induce an intense inflammatory host response in genetically susceptible individuals. Genetic studies have identified several susceptibility genes for KD and its sequelae in different ethnic populations, including FCGR2A, CD40, ITPKC, FAM167A-BLK and CASP3, as well as genes influencing response to intravenous immunoglobulin (IVIG) and aneurysm formation such as FCGR3B, and transforming growth factor (TGF) β pathway genes. IVIG and aspirin are effective therapeutically, but recent clinical trials and meta-analyses have demonstrated that the addition of corticosteroids to IVIG is beneficial for the prevention of coronary artery aneurysms (CAA) in severe cases with highest risk of IVIG resistance. Outside of Japan, however, clinical scores to predict IVIG resistance perform suboptimally. Furthermore, the evidence base does not provide clear guidance on which corticosteroid regimen is most effective. Other therapies, including anti-TNFα, could also have a role for IVIG-resistant KD. Irrespective of these caveats, it is clear that therapy that reduces inflammation in acute KD, improves outcome. This paper summarises recent advances in the understanding of KD pathogenesis and therapeutics, and provides an approach for managing KD patients in the UK in the light of these advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.